VNDA Stock Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.49|
|52 Week High||US$18.00|
|52 Week Low||US$9.24|
|1 Month Change||-1.13%|
|3 Month Change||-0.85%|
|1 Year Change||-35.25%|
|3 Year Change||-38.40%|
|5 Year Change||-25.34%|
|Change since IPO||8.37%|
Recent News & Updates
Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To BeFeb 27
An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% UndervaluedNov 01
Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?Jun 28
It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This YearJun 03
This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Mar 04
Vanda Pharmaceuticals Inc. Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen NextFeb 12
Are Insiders Selling Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock?Dec 23
How Does Vanda Pharmaceuticals' (NASDAQ:VNDA) CEO Pay Compare With Company Performance?Dec 02
|VNDA||US Biotechs||US Market|
Return vs Industry: VNDA underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: VNDA underperformed the US Market which returned -20.5% over the past year.
|VNDA Average Weekly Movement||4.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VNDA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VNDA's weekly volatility (5%) has been stable over the past year.
About the Company
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness.
Vanda Pharmaceuticals Inc. Fundamentals Summary
|VNDA fundamental statistics|
Is VNDA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VNDA income statement (TTM)|
|Cost of Revenue||US$24.28m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.11|
|Net Profit Margin||2.52%|
How did VNDA perform over the long term?See historical performance and comparison